RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/02/18	22:00	GlobeNewswire Inc.	Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/02/14	06:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/02/14	06:01	GlobeNewswire Inc.	Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/02/07	06:30	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/02/05	22:00	GlobeNewswire Inc.	Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reduction	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/01/18	06:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/01/13	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/01/13	01:00	GlobeNewswire Inc.	Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2025/01/07	06:30	GlobeNewswire Inc.	Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/21	06:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/20	06:17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/20	06:05	GlobeNewswire Inc.	Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/19	22:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/19	22:00	GlobeNewswire Inc.	Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/12/12	08:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/27	06:30	GlobeNewswire Inc.	Ultragenyx to Participate in Investor Conferences in December	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/21	06:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/12	20:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/10	00:30	GlobeNewswire Inc.	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/06	06:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/11/06	06:01	GlobeNewswire Inc.	Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/30	05:05	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/19	05:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/12	05:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/07	21:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/07	21:00	GlobeNewswire Inc.	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/04	05:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/10/04	05:30	GlobeNewswire Inc.	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/09/26	21:00	GlobeNewswire Inc.	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/09/19	06:00	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc